Elevance Health (ELV) Q2 2025 Earnings Transcript

Elevance Health cut full-year 2025 adjusted EPS guidance to approximately $30 from a higher prior target, citing persistent ACA medical cost inflation and slower Medicaid rate alignment. Q2 adjusted EPS was $8.84 on $49.4 billion of revenue, but the benefit expense ratio rose 260 bps to 88.9% and full-year benefit expense is now expected to be about 90%. Management said ACA morbidity and utilization remain elevated, Medicaid margin recovery will take longer, and buybacks continue but with greater flexibility.

Analysis

ELV is now trading like a cleaner quality compounder with a broken growth bridge: the market will likely punish the near-term reset, but the real issue is that a bigger share of earnings is being pushed into businesses with weaker pricing power and slower feedback loops. ACA and Medicaid are both facing lagged remediation, which means the next 2-3 quarters are less about operational execution and more about whether rate filings can outrun utilization before the 2026 bid cycle locks in. That timing mismatch matters because it creates a visible earnings trough even if management is eventually right on recovery.

Second-order winner: peers with more diversified earnings mix or less exchange exposure should look relatively better, while providers and niche vendors tied to aggressive coding, outpatient intensity, and behavioral health utilization may face a broader payer pushback cycle. ELV is signaling a more active payment-integrity regime, so hospitals and provider groups that rely on disputed claims, high-acuity coding lift, or ED-heavy utilization should expect tougher unit economics over the next 6-12 months. Carelon is the offset, but near-term margin dilution from scaling means investors are likely to underwrite that growth more skeptically until it proves it can absorb the core plan pressure.

The contrarian miss is that this may be less a one-quarter earnings issue and more a valuation reset for the entire managed care complex if subsidy expiration and work-requirement implementation amplify selection effects in 2026-27. The market appears to be treating the ACA morbidity shock as cyclical; if policy changes permanently shrink the healthier end of the exchange pool, the earnings power of individual-market products could structurally step down. On the flip side, if regulatory changes slow enrollment churn faster than expected, ELV has enough capital return capacity to re-rate quickly because the balance sheet is still intact and buybacks can re-accelerate once visibility improves.

Key Decisions for Investors

• Short ELV into the next 4-8 weeks on any relief rally; use a tight stop above the post-earnings gap-fill level. Risk/reward favors downside because consensus will need multiple quarters to regain confidence in 2026 earnings power.
• Pair long UNH / short ELV for the next 3-6 months to isolate execution and mix-quality divergence. ELV has more policy and exchange exposure, while UNH should screen better on earnings durability and capital deployment.
• Buy ELV Jan-2026 puts or put spreads on strength if implied volatility remains below historical post-reset levels. The setup is attractive if the market is underpricing the chance of another guidance cut tied to ACA utilization pull-through or Medicaid rate lag.
• For a lower-risk expression, rotate out of managed care names with heavier exchange exposure into names with more durable Medicare or services mix over the next 1-2 quarters. The key is avoiding names where rate-setting visibility is least synchronized with cost trend.
• Watch for a tactical long entry only if 2026 rate filings and state updates show clear sequential improvement; otherwise defer. The stock can work, but only after the market sees evidence that the rate lag is closing faster than utilization is worsening.